Breaking News
Statement from Steve Barclay, Secretary of State for Health and Social Care
Health and Social Care Secretary Steve Barclay said:
It is an honour to take up the position of Health and Social Care Secretary. Our NHS and social care staff have showed us time and again – throughout the pandemic and beyond – what it means to work with compassion and dedication to transform lives.
This government is investing more than ever before in our NHS and care services to beat the COVID-19 backlogs, recruit 50,000 more nurses, reform social care and ensure patients across the country can access the care they need.
People In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19
Senhwa Biosciences, a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and […]
Pneumagen Further Strengthens IP Protection for Lead Product Neumifil with Granting of US Composition of Matter Patent
Pneumagen, a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis […]
ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
Shionogi today announced that two late-breaking poster presentations featuring new results from the Phase 3 […]
PharmaJet Announces Clinical Results from Scancell’s COVID-19 DNA Vaccine Study Exclusively Administered with Needle-free Precision Delivery Systems
PharmaJet, a company engineering precision delivery systems that may overcome the challenges of nucleic acid […]
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted […]
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax’ COVID-19 Vaccine
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]
Roche launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-variant
Roche and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program
Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, […]